Evonik receives EXCiPACTTM certification for EUDRAGIT®

Evonik has received EXCiPACTTM certification for its EUDRAGIT®
products produced in Darmstadt. The EXCiPACTTM certificate
confirms that EUDRAGIT® is produced and sold in conformity with
the EXCiPACTTM guidelines for good manufacturing practice (GMP).

July 10, 2014

Contact person specialized press
Dr. Jürgen Krauter
Communication Health & Nutrition
Phone +49 (0)6181 59-6847
Fax +49 (0)6181 59-76847
juergen.krauter@evonik.com

Thanks to the EXCiPACTTM certification, Evonik's customers can restassured that the EUDRAGIT® products are of the highest quality.
“This certification shows that we are investing in product safety
and cost-efficiency for our customers," notes Dr. Jean-Luc
Herbeaux, head of the Health Care Business Line at Evonik. Evonikwill ensure the consistent safety and quality of EUDRAGIT®
products by undergoing recertification every three years andmonitoring audits annually.
On an increasing basis, both the U.S. Food and Drug
Administration (FDA) and the European Medicines Agency (EMA)
are requiring that pharmaceutical manufacturers provide proof thatthe excipients used in their products are of GMP-compliant quality.
This requires an increasing number of audits of excipient
suppliers, which involves correspondingly high investments in costand time. In these cases, EUDRAGIT® customers can use the audit
report that is part of the EXCiPACTTM certification.
The EXCiPACTTM standard was developed with input from industry
experts from all of the leading international pharmaceutical
excipients manufacturers and from pharmaceutical companies. It
complements the ISO 9001 norm and contains specificrequirements for the manufacture of excipients.

Company information
Evonik, the creative industrial group from Germany, is one of the world leadersin specialty chemicals. Profitable growth and a sustained increase in the value ofthe company form the heart of Evonik’s corporate strategy. Its activities focus on
the key megatrends health, nutrition, resource efficiency and globalization. Evonik
benefits specifically from its innovative prowess and integrated technology
platforms.
Page 1 of 2

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.deSupervisory BoardDr. Werner Müller, ChairmanExecutive Board
Dr. Klaus Engel, Chairman
Christian Kullmann
Thomas Wessel
Patrik Wohlhauser
Ute Wolf
Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

Evonik is active in over 100 countries around the world. In fiscal 2013 more than
33,500 employees generated sales of around €12.7 billion and an operating profit(adjusted EBITDA) of about €2.0 billion.

Disclaimer
In so far as forecasts or expectations are expressed in this press release or where
our statements concern the future, these forecasts, expectations or statements
may involve known or unknown risks and uncertainties. Actual results ordevelopments may vary, depending on changes in the operating environment.
Neither Evonik Industries AG nor its group companies assume an obligation to
update the forecasts, expectations or statements contained in this release.

Page 2 of 2